Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

Not Recruiting

Trial ID: NCT00952380

Age - N/A-18 Years Condition - Any Cancer Condition or Solid Tumor, Pediatric Cancer Gender - All Accepting Healthy Volunteers - No

Purpose

Three month treatment of acute VTE with Fragmin in pediatric cancer patients

Official Title

A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN(REGISTERED) (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES

Stanford Investigator(s)

Neyssa Marina

Eligibility


Inclusion Criteria:

-

Exclusion Criteria:

-

View More
View Less

Intervention(s):

drug: dalteparin

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
650-723-5535

New Trial Alerts

©2024 Stanford Medicine